Combination Therapy for Melanoma
Author Information
Author(s): N.H. Mulder, E.G.E. de Vries, D.Th. Sleijfer, H. Schraffordt Koops, P.H.B. Willemse
Primary Institution: University Hospital Groningen
Hypothesis
Does the combination of Dacarbazine, alpha-interferon, and 5-fluorouracil improve treatment outcomes in patients with disseminated malignant melanoma?
Conclusion
The study found a 38% response rate in patients treated with the combination therapy, indicating some effectiveness but not a major impact from adding 5-FU.
Supporting Evidence
- The combination therapy resulted in a 38% response rate.
- Median survival for all patients was 12 months.
- Patients experienced significant toxicity, primarily nausea and vomiting.
Takeaway
Doctors tested a new treatment for skin cancer and found that it helped some patients, but not as many as they hoped.
Methodology
The study involved administering a combination of Dacarbazine, alpha-interferon, and 5-fluorouracil to 26 patients with disseminated malignant melanoma and evaluating their responses.
Potential Biases
Potential bias due to the small number of patients and the exclusion of those with central nervous system metastasis.
Limitations
The response rates were lower than expected, and the study had a small sample size.
Participant Demographics
Median age of patients was 44 years, with a range from 15 to 57 years; 11 were female.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% confidence level 20-59%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website